BioSpace News Archive

Cenobamate significantly reduced focal seizure frequency, with as many as 20% of patients reaching zero seizures during the study’s maintenance phase

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced the pricing of an underwritten public offering of 2,400,000 shares of its Class A common stock at a price to the public of $183.00 per share.

BioCryst Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 37,931,035 shares of its common stock, offered at a price to the public of $1.45 per share.

Ritter Pharmaceuticals, Inc. reported recent business developments and financial results for the three and nine months ended September 30, 2019.

Halozyme Therapeutics, Inc., a biotechnology company focused on novel biological and drug delivery approaches, announced the pricing of $400.0 million aggregate principal amount of its convertible senior notes due 2024

Fulgent Genetics announced the pricing of its previously announced underwritten public offering of 2,325,000 shares of its common stock at a public offering price of $11.25 per share, resulting in gross proceeds of approximately $26.2 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.

Leading immuno-oncology company adopts Genedata Biologics® to support the discovery and development of TCRs for adoptive cell therapies and bispecific TCR molecules

The ISO 13485 audit is an essential qualification for medical device manufacturers, showing HRA Pharma’s commitment to the highest quality standard.

The TGaS® Advisors 2019 Fall Summit, “Becoming Indispensable Business Partners: Overcoming Obstacles in Today’s Challenging Healthcare Environment,” brought together nearly 150 pharmaceutical professionals representing 66 companies.

Mongeau to leverage experience and relationships in the space to lead sleep and respiratory divisions’ continued national growth